[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-eye-disease-ded\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-eye-disease-ded":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,41,64,92,121,143,165,185,204,230,257,279,301,328,346,366,390,409,430,454,479,503,522,543,567],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641239","phase-2-dose-finding-study-of-huc1-394-in-participants-with-dry-eye-disease-100641239",false,"NCT07656688","Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of HUC1-394 in Participant With Dry Eye Disease","Inclusion Criteria:\n\n* Adults aged ≥ 19 years at the time of screening\n* Trial participants who have experienced at least one of the following dry eye disease symptoms for at least 3 months prior to the time of screening\n* Trial participants who meet all of the following criteria in at least one eye (left or right) at the time of screening and randomization:\n\nTCSS (NEI grading) ≥ 4 \u002F Non-anesthetic Schirmer test result \\> 0 mm and ≤ 10 mm\u002F5 min \u002F TBUT \\\u003C 7 seconds\n\n* OSDI score ≥ 23 at the time of screening\n* Trial participants who have provided voluntary written informed consent after receiving a full explanation and understanding of the clinical trial\n\nExclusion Criteria:\n\n* Trial participants with clinically significant ophthalmic diseases that may confound the interpretation of clinical trial results\n* Trial participants with blepharospasm, entropion, ectropion, or abnormalities of the eyelashes\n* Trial participants with any active ophthalmic disease that may affect the ocular surface, such as active allergy, anterior uveitis, and Stevens-Johnson syndrome\n* Trial participants with a history of corneal transplantation or neurotrophic keratitis\n* Trial participants with autoimmune diseases or immunodeficiency disorders\n* Pregnant or lactating women, or women of childbearing potential and men of reproductive potential who plan to conceive during the clinical trial or are unwilling to use an appropriate method of contraception\n* Trial participants who have participated in another clinical trial and received an investigational product or used an investigational medical device within 30 days prior to the time of screening\n* Trial participants who are deemed ineligible for participation by the investigator for any other reason in the clinical trial","ALL","19 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.",[27],"Dry Eye Disease (DED)","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2027-07",{"name":38,"class":39},"Huons Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100645006","phase-4-randomized-single-center-study-to-evaluate-tolerability-symptoms-and-visual-functional-outcomes-with-the-use-of-otc-lubricating-eye-drops-in-subjects-with-dry-eye-disease-100645006","NCT07676084","Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease","A Randomized, Investigator-Masked, Single-Center Study Evaluating Tolerability, Symptomatic Improvement, and Visual Functional Outcomes With the Use of Over-the-Counter Lubricating Eye Drops in Subjects With Dry Eye Disease","Inclusion Criteria:\n\n1. Be at least 18 years of age, male or female\n2. Able to provide written voluntary informed consent\n3. Able and willing to adhere to the protocol instructions, including participation in all study visits\n4. Subject-reported symptoms or history consistent with dry eye for at least 6 months prior to Screening\u002FBaseline (Visit 1)\n5. Ocular Surface Disease Index (OSDI) score \\>13\n\nExclusion Criteria:\n\nNote: All ocular exclusion criteria apply to either eye.\n\n1. DED secondary to destruction of conjunctival goblet cells due to ocular trauma (eg, alkali burns) or ocular or systemic condition (eg, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, Vitamin A deficiency)\n2. Any abnormal lid or corneal anatomy that would interfere with eyelid closure or create an irregular ocular tear film\n3. Any active ocular infection, inflammation, or ocular allergy\n4. Have undergone ocular surgery or laser refractive surgery within 9 months prior to Screening\u002FBaseline (Visit 1)\n5. Use of LipiFlow® procedure, intense pulse light procedure, or any kind of other procedure affecting meibomian glands within 6 months prior to Screening\u002FBaseline (Visit 1)\n6. Occlusion of the ocular puncta within 30 days prior to Screening\u002FBaseline (Visit 1)\n7. Have worn contact lenses within 3 days prior to Screening\u002FBaseline (Visit 1) or planned wear during the study\n8. Use of topical prescription products for dry eye, including topical ocular anti inflammatories (eg, cyclosporine, lifitegrast), corticosteroids, MIEBO® (perfluorohexyloctane ophthalmic solution), or TRYPTYR® (alcotremon ophthalmic solution) within 30 days prior to Screening\u002F Baseline (Visit 1)\n9. Use of any eye drops (prescription or OTC, such as artificial tears or Lumify®) and\u002For TrueTear™ device (intranasal tear neurostimulator) within 24 hours prior to Screening\u002F Baseline (Visit 1)\n10. Changes in any systemic medications known to impact tear production (eg, antihistamines, antidepressants, hormone replacement therapy, etc.) within 3 months prior to Screening\u002FBaseline (Visit 1)\n11. Have a serious or uncontrolled systemic disease (eg, diabetes, rheumatoid arthritis, lupus, hypertension, malignancy) that, in the opinion of the Investigator, will interfere with the study or interpretation of study results","18 Years",{"count":50,"type":21},60,[52],"PHASE4","A study to evaluate the effect of over- the- counter (OTC) lubricating eye drops on tolerability, symptoms and visual outcomes in patients with dry eye disease (DED)",[27],"2026-06-24",{"date":57,"type":32},"2026-06-30",{"date":59,"type":32},"2026-06-03",{"date":61,"type":21},"2026-12",{"name":63,"class":39},"Andover Research Eye Institute",{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":76,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100631684","phase-2-an-exploratory-efficacy-and-safety-study-of-dfl24498-topical-ophthalmic-solution-compared-with-vehicle-in-participants-with-dry-eye-disease-100631684","NCT07503886","An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease","A 12-Week, Phase 2, Multicenter, Randomized, Double-Masked, Vehicle Controlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate the Efficacy and Safety of DFL24498 0.08% Topical Ophthalmic Solution Versus Vehicle in Participants With Dry Eye Disease","Key Inclusion Criteria:\n\n* A diagnosis of DED at least 6 months before enrollment (current use or recommended use of artificial tears for the treatment of dry eye).\n* The global score of the SANDE questionnaire ≥ 30\n* DED in at least one eye which is characterized by the following clinical features:\n\n  1. Schirmer I test without anesthesia \\\u003C 10 mm\u002F5 minutes, and\n  2. Total CFS grade ≥ 4 assessed by the NEI grading system, and\n  3. Fluorescein tear film break-up time (TFBUT) \\\u003C 10 seconds.\n* Best corrected visual acuity (BCVA) score on early treatment of diabetic retinopathy study (ETDRS) chart of ≥ 35 letters (corresponding to ≥ 0.1 Snellen decimal units or ≤ 1.0 Logarithm of the Minimum Angle of Resolution (Chart) \\[LogMAR\\]) in each eye at the time of study enrollment.\n* Only participants who satisfy all informed consent requirements will be included in the study.\n\nKey Exclusion Criteria:\n\n* Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.\n* Evidence of an active ocular infection in either eye.\n* Anticipated need for ocular surgery during the study period, or any prior ocular surgery for 6 months prior to screening.\n* Intraocular inflammation defined as anterior chamber cell or flare \\> 0 by Standardization of Uveitis Nomenclature (SUN) grading in either eye.\n* Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa) in either eye.\n\nNote: Additional protocol defined Inclusion\u002FExclusion criteria apply.",{"count":72,"type":21},417,[24],"This is a Phase 2, randomized, multicenter, double masked, vehicle controlled, parallel group study to evaluate the efficacy and safety of DFL24498 topical ophthalmic solution versus vehicle in participants with dry eye disease. Approximately 417 participants aged 18 years or older who meet all eligibility criteria will be enrolled at study sites in the US. The study duration will be up to 16 weeks and will consist of three periods.",[27],[77,78,79,80,81],"Dry Eye Disease","DFL24498","Ocular discomfort","Eye dryness","Topical ophthalmic solution","2026-06-23",{"date":84,"type":32},"2026-06-26",{"date":86,"type":32},"2026-05-12",{"date":88,"type":21},"2027-02-07",{"name":90,"class":39},"Dompé Farmaceutici S.p.A",24,{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":116,"leadSponsor":118,"locationsCount":40},"100644483","phase-2-safety-and-efficacy-of-topical-infliximab-in-autoimmune-dry-eye-disease-100644483","NCT07671222","Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease","Safety and Efficacy of Topical Infliximab Versus Topical Steroid in Autoimmune Dry Eye Disease: Randomized Controlled Trial.","INFLIXIDRY","Inclusion Criteria:\n\n* Adult patients (≥ 18 years).\n* Confirmed diagnosis of primary or secondary Sjögren's syndrome according to the 2016 ACR\u002FEULAR classification criteria.\n* On stable systemic immunomodulatory therapy (non-biologic) for at least 12 weeks, with no planned changes during the study (see section 14.1 if there are concerns about confounding variables).\n* Negative chest X-ray or Interferon-Gamma Release Assays (IGRA).\n* Diagnosis of severe dry eye, defined by meeting all of the following criteria in at least one eye at study entry:\n* OSS (SICCA 0-12) ≥ 6 in at least one eye.\n* OSDI ≥ 33 (severe symptoms).\n* Symptoms: OSDI score ≥ 33.\n* Signs: Ocular Staining Score (OSS, SICCA) ≥ 6.\n* Ability to understand and sign informed consent and to comply with study procedures and treatment administration.\n\nExclusion Criteria:\n\n* Current use of topical corticosteroids or topical immunomodulators (cyclosporine, lifitegrast, tacrolimus, autologous serum) within 30 days prior to enrollment.\n* Current or recent use (\\\u003C 3 months) of punctal plugs.\n* Active ocular infection (bacterial, viral, fungal) or recent history of herpetic keratitis.\n* Ocular or eyelid surgery within the past 6 months.\n* Use of contact lenses during the study period.\n* Known allergy or hypersensitivity to infliximab, murine proteins, or any component of the formulation (including CMC).\n* Coexisting ocular conditions that may interfere with dry eye evaluation (e.g., active ocular cicatricial pemphigoid, active ocular graft-versus-host disease, uncontrolled glaucoma, significant corneal dystrophy).\n* Systemic conditions considered contraindications to infliximab exposure, including: active systemic infection, untreated active or latent tuberculosis, history of demyelinating disease, moderate to severe congestive heart failure (NYHA Class III\u002FIV), or history of malignancy within the past 5 years.\n* Use of systemic biologic agents within the past 6 months (12 months for systemic anti-TNF-α therapy).\n* Pregnancy, breastfeeding, or intention to become pregnant during the study.\n* Participation in another clinical trial with an investigational drug within the past 30 days.\n* Ability to understand and sign informed consent and to comply with study procedures and treatment administration.",{"count":101,"type":21},38,[24],"Sjögren's syndrome is a condition in which the immune system attacks the body's moisture-producing glands. This often causes severe dry eye, leading to discomfort, irritation, blurred vision, and damage to the eye surface. Inflammation plays an important role in this process, and a protein called TNF-alpha is one of the key drivers.\n\nThis study will test a new eye drop containing infliximab, a medication that blocks TNF-alpha. The goal is to see whether this treatment can safely improve symptoms and signs of severe dry eye in patients with Sjögren's syndrome.",[105,106,27],"Sjogren Syndrome","Sjogren Syndrome With Keratoconjunctivitis",[108,109,110,111],"Dry eye disease","Sjogren syndrome","Sjogren disease","Autoimmune dry eye","NOT_YET_RECRUITING","2026-06-22",{"date":84,"type":32},{"date":61,"type":21},{"date":117,"type":21},"2028-03",{"name":119,"class":120},"Instituto de Oftalmología Fundación Conde de Valenciana","OTHER",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100642261","phase-4-a-multicenter-open-label-study-to-evaluate-perioperative-treatment-of-dry-eye-with-miebo-in-subjects-undergoing-lasik-100642261","NCT07650708","A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK","Sonoran","Inclusion Criteria:\n\n1. Be at least 18 years of age at the time of consent, able to provide written voluntary informed consent, willing to follow instructions and participate in all trial assessments and visits\n2. Be a candidate for routine, uncomplicated bilateral LASIK surgery (for spherical equivalent \\[≤-8.00D\\] myopia or myopic astigmatism correction, not combined with any other procedure; monovision myopic targets are allowed, however the myopic target eye will be the non-study \\[fellow\\] eye)\n3. No history of refractive surgery including implantable Collamer lens (ICL) or cataract surgery\n4. Total CFS score ≥1 and ≤6 using the National Eye Institute scale at Visit 1 (in at least one eye)\n5. Ocular Surface Disease Index (OSDI) ≥13 and ≤22 at Visit 1\n\nExclusion Criteria:\n\n1. Have any clinically significant ocular surface slit-lamp findings in the study eye that, in the opinion of the Investigator, could interfere with outcomes of a routine, uncomplicated LASIK surgery, including but not limited to:\n\n   1. History of eye trauma\u002Fsurgery within the last 6 months that resulted in corneal scarring\n   2. DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells, Stevens-Johnson syndrome, active blepharitis, or lid margin inflammation\n   3. Abnormal cornea (e.g., keratoconus or corneal epithelial defect, pterygium, or history of herpetic keratitis)\n2. Use of any of the following ocular therapies in the study eye within 30 days prior to Visit 1: topical ocular steroid treatments, prescription dry eye therapy (including nasal spray), or topical intraocular pressure-lowering medications\n3. Use of any eye drops (prescription or over the counter) in the study eye within 24 hours prior to Visit 1\n4. Use of any oral medications known to cause ocular drying (e.g., antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or is expected to be unstable during the trial\n5. Had a LipiFlow®, intense pulsed light (IPL) therapy, etc. in the study eye within 3 months prior to Visit 1\n6. Had received or removed a permanent punctum plug in the study eye within 1 month (3 months for dissolvable punctum plugs) prior to Visit 1\n7. Have worn soft contact lenses within either 3 days prior to the study or rigid gas-permeable contact lenses for 1 month prior to Visit 1 or any planned wear during the study\n8. Have undergone intraocular surgery or ocular laser surgery in the study eye within 3 months prior to Visit 1\n9. Have ocular allergies that are\u002Fexpected to be active during the trial period\n10. Have active ocular or systemic infection (bacterial, viral, or fungal), including fever\n11. Have any ocular findings or uncontrolled systemic disease that, in the opinion of the Investigator, will interfere with the trial\n12. Female subjects who are pregnant, nursing, or planning a pregnancy\n13. Female subjects of childbearing potential who are not using an acceptable means of birth control; acceptable methods of contraception include hormonal (oral, implantable, injectable, or transdermal) contraception; mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom) contraception; intrauterine device; or surgical sterilization of partner. For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.\n14. Have a known allergy and\u002For sensitivity or lack of desired efficacy in response to the investigational drug\n15. Are currently enrolled in an investigational drug or device study or had used an investigational drug or device within 30 days prior to Visit 1 -",{"count":129,"type":21},100,[52],"Compare eye dryness following laser-assisted in situ keratomileusis (LASIK) surgery to eye dryness prior to receiving perioperative Miebo in patients with dry eye disease (DED)",[133,27],"Dry Eye Syndrome (DES)","2026-06-19",{"date":55,"type":32},{"date":137,"type":32},"2026-05-05",{"date":139,"type":21},"2026-12-01",{"name":141,"class":120},"Vance Thompson Vision",4,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":161,"leadSponsor":163,"locationsCount":40},"100643713","the-effect-of-eyelid-support-plate-assisted-eyelid-massage-on-meibomian-gland-dysfunction-a-randomized-controlled-trial-100643713","NCT07633938","The Effect of Eyelid Support Plate Assisted Eyelid Massage on Meibomian Gland Dysfunction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Voluntarily participate and sign an informed consent form;\n2. Age range: 18 to 60 years old;\n3. Meet the diagnostic criteria for dry eye in the International Society of Tears and Ocular Surface (TFOS) Dry Eye Symposium (DEWS) II ;\n4. 1\u002F3 or more of the meibomian gland openings are blocked or the secretion characteristics of the meibomian gland are abnormal;\n5. The best corrected visual acuity for each eye is ≥ 0.5;\n6. Eye pressure (IOP) ≥ 5mmHg and ≤ 21mmHg per eye;\n7. Women with reproductive potential agree to use reliable contraceptive methods during the study period;\n8. Willing and able to complete all planned research visits and follow the guidance of the researchers.\n\nExclusion Criteria:\n\n1. Contact lens use: Having used contact lenses within 14 days prior to the screening visit, or refusing to commit to discontinuing contact lens use during the study period (within the next 2 months);\n2. Had undergone corneal refractive surgery (e.g., LASIK\u002FSMILE), other corneal surgeries, cataract surgery, anti-glaucoma surgery, or fundoscopic surgery within 12 months prior to enrollment screening;\n3. Participation in other medical studies within 3 months prior to enrollment screening;\n4. Presence of any of the following active ocular diseases at present or within 3 months prior to screening: I) Acute allergic conjunctivitis; II) Infection (by bacteria, viruses, fungi, etc.); III) Inflammation (e.g., keratitis, retinitis).\n\n   Meningitis, choroiditis, uveitis, scleritis, etc.;\n5. Eyelid abnormalities affecting eyelid function (such as ptosis, blepharospasm, entropion, ectropion, etc.);\n6. Extensive ocular surface scars or conditions that may compromise ocular surface integrity (e.g., Stevens-Johnson syndrome, history of chemical burns, persistent corneal epithelial defects, history of ocular trauma, etc.);\n7. Currently or previously diagnosed with glaucoma, or undergoing treatment with anti-glaucoma medications;\n8. Has used any of the following ocular medications within the past 1 month: immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or perfluorohexyloctane;\n9. Has received any of the following non-pharmacological treatments for dry eye within the past month: meibomian gland massage, deep eyelid margin cleansing, intense pulsed light therapy, or thermal pulsation therapy;\n10. During pregnancy or lactation;\n11. Neurological or psychiatric disorders (moderate to severe anxiety, depression, and sleep disorders);\n12. Uncontrolled ocular or systemic diseases;\n13. History of epilepsy;\n14. The investigator determines that the subject is not suitable for participation in this study.","60 Years",{"count":151,"type":21},142,[153],"NA","This study aims to conduct a randomized controlled clinical trial to compare the efficacy of a new type of massage device - eyelid support plate and glass rod assisted eyelid massage in improving MGD related dry eye symptoms, and evaluate the comfort and efficiency of both treatments, providing evidence-based support for clinical work",[27,156],"MGD-Meibomian Gland Dysfunction","2026-06-08",{"date":159,"type":32},"2026-06-11",{"date":31,"type":21},{"date":162,"type":21},"2027-09-01",{"name":164,"class":120},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":40},"100643548","phase-4-randomized-clinical-trial-of-artificial-tears-with-and-without-preservatives-in-patients-with-dry-eye-disease-100643548","NCT07635849","Randomized Clinical Trial of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease","Comparative Effectiveness of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical diagnosis of Dry Eye Disease (OSDI \\>13 and TBUT \\\u003C10 seconds)\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Contact lens use\n* Active ocular infection or inflammation\n* History of ocular surgery within the past 6 months\n* Use of systemic immunosuppressive therapy",{"count":173,"type":21},80,[52],"Dry Eye Disease (DED) is a common, chronic ocular surface disorder characterized by tear film instability, ocular discomfort, and visual disturbance. Artificial tears are the first-line treatment for DED; however, many formulations contain preservatives such as benzalkonium chloride (BAK) and stabilized oxychloro complex (SOC) which may cause ocular surface toxicity with long-term use. Preservative-free artificial tears are considered safer alternatives, but comparative clinical evidence from Nepal is limited. This study aims to compare the clinical efficacy and safety of preservative-free versus preserved carboxymethylcellulose (CMC) artificial tears in patients with Dry Eye Disease. This will be a hospital-based, randomized, double-blinded controlled clinical trial conducted in the ophthalmology outpatient department of a tertiary care hospital in Nepal. A total of 80 adult patients diagnosed with Dry Eye Disease will be enrolled and randomly allocated in a 1:1 ratio to receive either preservative-free CMC artificial tears or preserved CMC artificial tears for a duration of eight weeks. Participant, investigators, outcome assessors and data analysts will remain blinded to minimize assessment bias. Baseline assessments will include the Ocular Surface Disease Index (OSDI) questionnaire, Tear Film Break-Up Time (TBUT), Schirmer's test (without anesthesia), and corneal fluorescein staining. These outcomes will be reassessed at four and eight weeks. Safety and tolerability will be evaluated by documenting patient-reported adverse effects. Data will be analyzed using appropriate statistical methods, with a p-value of less than 0.05 considered statistically significant. The study is expected to demonstrate superior safety and improved ocular surface outcomes with preservative-free artificial tears compared to preserved formulations. Findings from this research will provide local evidence to guide rational prescribing practices and improve the management of Dry Eye Disease in Nepal.",[27],{"date":178,"type":32},"2026-06-10",{"date":34,"type":21},{"date":181,"type":21},"2027-03",{"name":183,"class":184},"Pokhara Academy of Health Sciences, Western Regional Hospital","OTHER_GOV",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":4},"100621282","phase-4-comparison-of-conjunctival-goblet-cell-density-in-dry-eye-patients-treated-with-cyclosporine-01-dissolved-in-perfluorobutylpentane-vevye-or-generic-005-cyclosporine-emulsion-for-8-weeks-100621282","NCT07368595","Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","CSAGCD","Inclusion Criteria:\n\n* 1\\. Male or female, 18 years of age or older at enrollment. 2. Have a history of DED, clinician diagnosed or patient reported, within the 6 months prior to the enrollment visit.\n\n  3\\. Have both of these signs of DED in the same eye at the Enrollment (baseline) visit:\n  1. Total cornea fluorescein staining score ≥ 3 based on the modified National Eye Institute (NEI) grading scheme.\n  2. Total conjunctival lissamine green staining score ≥ 2 based on the modified NEI grading scheme. 4. Unanesthetized Schirmer test score ≥ 5 and \\\u003C 15mm\u002F5 min in at least 1 eye at the enrollment visit.\n\n     5\\. A SANDE eye discomfort visual analog questionnaire score of ≥ 35 at the enrollment visit.\n\n     6\\. Good general and ocular health, as determined by the investigator using medical history and ophthalmic examination.\n\n     7\\. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\n     8\\. Have given written informed consent prior to any study related procedures. 9. Able and willing to follow study instructions and likely to complete all required study visits as assessed by the investigator.\n\n     Exclusion Criteria:\n* Inclusion Criteria:\n\nTo be eligible to participate in this trial, an individual must meet all the following criteria:\n\n1. Male or female, 18 years of age or older at enrollment.\n2. Have a history of DED, clinician diagnosed or patient reported, within the 6 months prior to the enrollment visit.\n3. Have both of these signs of DED in the same eye at the Enrollment (baseline) visit:\n\n   1. Total cornea fluorescein staining score ≥ 3 based on the modified National Eye Institute (NEI) grading scheme.\n   2. Total conjunctival lissamine green staining score ≥ 2 based on the modified NEI grading scheme.\n4. Unanesthetized Schirmer test score ≥ 5 and \\\u003C 15mm\u002F5 min in at least 1 eye at the enrollment visit.\n5. A SANDE eye discomfort visual analog questionnaire score of ≥ 35 at the enrollment visit.\n6. Good general and ocular health, as determined by the investigator using medical history and ophthalmic examination.\n7. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n8. Have given written informed consent prior to any study related procedures.\n9. Able and willing to follow study instructions and likely to complete all required study visits as assessed by the investigator.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria at the enrollment visit will be excluded from entry into the study:\n\nOphthalmic:\n\n1. History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety, such as: significant conjunctival scarring; pterygium or nodular pinguecula; conjunctivitis, or inflammation not associated with DED; clinically significant anterior blepharitis (Staphylococcal or Demodex).\n2. Other significant ophthalmic disease requiring topical medication (e.g., glaucoma, ocular hypertension), or other ophthalmic disease which the investigator believes may interfere with study findings or interpretation.\n3. History of ocular surgery within 1 year prior to the Screening visit, including punctal cautery, corneal refractive, or anterior segment surgeries (e.g., cataract surgery or any surgery creating limbal or corneal incisions).\n4. History of corneal transplant in one or both eyes.\n5. Diagnosis of recurrent, ongoing, or active ocular infection including, but not limited to herpes simplex or zoster, bacterial or fungal keratitis.\n6. Use of contact lenses in either eye within 90 days prior to the enrollment visit or planned use during the study.\n7. Punctal or intracanalicular plug present in either eyelid within 90 days prior to the enrollment visit or anticipated plug insertion or occlusion at any time during the study.\n8. Regular use, as assessed by the investigator, of lid hygiene or heat masks within 14 days prior to the Enrollment visit or any planned use during the study.\n9. Use of lid heating therapy (i.e., LipiFlow®, iLUX®, Thermal OneTouch, TearCare®) or Meibomian gland probing\u002Ftherapeutic expression within 90 days prior to enrollment or anticipated during the study.\n10. Use of Intense Pulsed Light (IPL) therapy on eyelids within 90 days prior to enrollment or anticipated during the study.\n11. Use of artificial tears within 24 hours prior to enrollment or anticipated use during the study.\n12. Use of any topical ocular cyclosporine A formulation (e.g., ocular cyclosporine \\[Restasis®, Cequa™, Vevye™, generics\\] within 1 year prior to enrollment. Use of lifitegrast \\[Xiidra®\\]), perfluorohexyloctane \\[Meibo™\\]), Tryptyr™, or any topical ocular corticosteroid, or any non-steroidal-anti-inflammatory agents within 90 days prior to enrollment or anticipated use during the study.\n13. Use of topical ocular autologous serum\u002Fplasma within 90 days prior to the enrollment or anticipated use during the study.\n14. Use of any topical ocular glaucoma medication within 30 days prior to enrollment or anticipated use during the study.\n15. Regular use, as defined by the investigator, of any other topical ocular medication not listed in Exclusion 11, 12, 13 or 14 within 14 days prior to the enrollment visit or anticipated use during the study (e.g., eye whitening products \\[Visine®, Lumify®\\], topical ocular antibiotics, topical ocular antihistamines, mast cell stabilizers, presbyopia correcting drops \\[e.g., Vuity™\\].\n16. Use of Tyrvaya™ (varenicline solution, nasal spray 0.03 mg) within 90 days prior to the enrollment visit or anticipated use during the study.\n17. Use of oral medications for the treatment of severe DED and\u002For Meibomian gland disease such as oral pilocarpine, oral cevimeline, oral macrolides, oral tetracyclines or tetracycline derivatives, and oral retinoids within 30 days prior to enrollment or anticipated use during the study.\n18. General\u002FSystemic:\n\n    Initiation, discontinuation, or change in dose of a systemic medication known to cause ocular drying (e.g., antihistamines or antidepressants) less than 30 days prior to enrollment or a change in dosage is anticipated during the study. Note: occasional short-term use of these medications, such as systemic antihistamines will be permitted, provided that use was not within 7 days prior to enrollment. Initiation, discontinuation, or change in dose of a systemic corticosteroid less than 60 days prior to the enrollment visit or a change in dosage is anticipated during the study. Note: Non-ocular topically applied corticosteroids (including topical creams, nasal sprays and inhalers) will be permitted during the study, and the dose is not required to be stable.\n19. Initiation, discontinuation, or change in dose of a systemic immunomodulator (e.g., hydroxychloroquine, methotrexate, cyclosporine) less than 60 days prior to the enrollment visit or a change in dosage is anticipated during the study.\n20. Use of an investigational product or device within 30 days prior to the Screening visit.\n21. At the enrollment visit, at the investigator's discretion, have uncontrolled or severe:\n\n    1. Systemic allergy\n    2. Rhinitis or sinusitis\n    3. Atopic dermatitis involving the eyelids\n22. History or presence of significant systemic disease (i.e.: cardiovascular, pulmonary, hepatic, renal, hematologic, immunologic). Significant is defined as any disease that, in the assessment of the Investigator, would put the safety of the subject at risk through participation, or would prevent or confound protocol-specified assessments (e.g., severe rheumatoid arthritis, severe systemic lupus erythematosus, uncontrolled immunodeficiency disease, etc.).\n23. Known allergies or sensitivity to the study interventions or study diagnostic agents, including sodium fluorescein, lissamine green, etc.\n24. Pregnant at enrollment, currently breastfeeding or plans to become pregnant or breastfeed during the study.",{"count":50,"type":21},[52],"This goal of this clinical trial is to compare the effects of two approved cyclosporine eye drops that have different concentrations and vehicles on the number of mucus producing conjunctival goblet cells in patients with dry eye disease to learn which one causes the greatest increase.\n\nThe main questions it aims to answer are:\n\nDoes one drug cause a greater increase in goblet cells? How many weeks does it take to see the difference?\n\nParticipants will:\n\nUse the eye drops every day for 2 months Visit the clinic once every 2 weeks for exams and tests",[27],"2026-06-02",{"date":59,"type":32},{"date":199,"type":21},"2026-09-01",{"date":201,"type":21},"2027-06",{"name":203,"class":120},"Baylor College of Medicine",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":212,"phases":4,"briefSummary":213,"conditions":214,"keywords":220,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":40},"100639891","impact-of-glp-1-receptor-agonists-on-dry-eye-disease-in-patients-with-type-2-diabetes-mellitus-and-obesity-100639891","NCT07605572","Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity","GALENOS","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Patients who have not previously received GLP-1 receptor agonists (GLP-1 RAs).\n3. Patients able to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients.\n2. History of multiple severe hypoglycemic episodes within the past two years.\n3. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis.\n4. Patients who have undergone cataract surgery or vitrectomy within the past 6 months.\n5. History of ketoacidosis or metabolic acidosis.\n6. History of corneal transplantation.",{"count":129,"type":21},"OBSERVATIONAL","Diabetes mellitus (DM), prediabetes, and obesity are emerging as major global public health problems, with their epidemic spread continuously increasing over the past decades. The occurrence of diabetic retinopathy, cataract, glaucoma, and ocular surface disease in patients with diabetes mellitus has been extensively investigated in several studies. However, mild ocular surface disorders, such as dry eye disease, have often been overlooked, with a previous study showing that 51.3% of diabetes-related dry eye disease cases remained underdiagnosed. Among systemic diseases, diabetes mellitus and obesity have been associated with an increased risk of developing dry eye disease. Chronic hyperglycemia in diabetes leads to microvascular damage, including corneal neuropathy and reduced tear production, conditions that can disrupt ocular surface health, while systemic inflammation and meibomian gland dysfunction also contribute to this process. However, the effect of newer classes of antidiabetic medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), on ocular surface health remains insufficiently understood. The aim of this prospective cohort study is to evaluate the effects of GLP-1 receptor agonists on dry eye disease in patients with type 2 diabetes mellitus and obesity through the assessment of ocular surface parameters, such as tear film break-up time, Schirmer test results, as well as potential changes in corneal topography.",[27,215,216,217,218,219],"Diabete Mellitus","GLP-1","Ocular Surface","Diabetes Type 2","Cornea",[108,218,221,219],"GLP-1 Receptor Agonists","2026-05-29",{"date":196,"type":32},{"date":225,"type":32},"2026-03-01",{"date":227,"type":21},"2027-02-28",{"name":229,"class":120},"Attikon Hospital",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":256},"100635126","phase-2-a-clinical-study-evaluating-licaminlimab-for-dry-eye-disease-100635126","NCT07548632","A Clinical Study Evaluating Licaminlimab for Dry Eye Disease","A Phase 2b\u002F3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype","PREDICT-1","Key Inclusion Criteria:\n\n* Physician diagnosis of Dry Eye Disease in the past 6 months\n* Use of over-the-counter tears\n* Must agree to genotype testing\n\nKey Exclusion Criteria:\n\n\\- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.",{"count":239,"type":21},160,[24,241],"PHASE3","The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.",[27],[245,246,236,247,248],"licaminlimab","OCS-02","genotype based development","Eye drops","2026-05-27",{"date":222,"type":32},{"date":252,"type":32},"2026-04-16",{"date":61,"type":21},{"name":255,"class":39},"Oculis",14,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":40},"100626061","briter-eyez-moisture-vue-on-demand-disposable-moisture-chamber-100626061","NCT07430735","BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber","A Clinical Evaluation of the BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber in Subjects With Mild to Moderate Dry Eye Disease","Inclusion Criteria:\n\n* 18 years of age or older\n* Clinical Diagnosis of mild to moderate dry eye\n* Individual wears eyeglass spectacles\n\nExclusion Criteria:\n\n* Children under the age of 18 years of age\n* Women who are currently pregnant or nursing\n* Adults with decisional impairment\n* Prisoners\n* Individuals who have a known ocular or medical condition (other than DED) that impacts their ocular surface and could confound the results of the study.",{"count":265,"type":21},35,[153],"The purpose of this study is to evaluate the short-term effects (impact on tear film and dry eye symptoms) of the BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber (the device under investigation) in individuals with mild to moderate dry eye disease. Specifically, the study aims to determine whether wearing the device for two hours improves tear-film stability, tear volume, and tear osmolarity,",[27],[270],"Dry Eye",{"date":272,"type":32},"2026-05-15",{"date":274,"type":21},"2026-06-01",{"date":276,"type":21},"2027-07-01",{"name":278,"class":120},"University of Rochester",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":299,"locationsCount":40},"100566458","phase-4-the-effects-of-3-trehalose-ophthalmic-solution-on-corneal-epithelial-barrier-function-100566458","NCT06655441","The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function","Inclusion Criteria:\n\n* Adult subjects, \\> age 18 years, with moderate-to-severe dry eye, defined as fitting criteria for dry eye stages 3 or 4 of the MGD Workshop Management and Treatment subcommittee report.\n* Subjects must have normal eyelid position and closure.\n* For enrollment as aqueous tear deficiency, subjects must have a Schirmer I result of \\\u003C 5.0 mm wetting in 5 minutes without anesthesia.\n\nExclusion Criteria:\n\n* History or evidence of ocular or intraocular surgery in either eye within the past twelve months. LASIK and other kerato-refractive procedure patients can qualify if the most recent surgery or enhancement was 12 or more months prior.\n* History or evidence of serious ocular trauma in either eye within the past six months.\n* History of hypersensitivity to any component of the study medications.\n* History or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia, active or recent varicella, viral disease of the cornea and\u002For conjunctiva; chronic bacterial disease of the cornea and\u002For conjunctiva; mycobacterial infection of the eye; and\u002For fungal disease of the eye.\n* History or evidence of active ocular allergy.\n* Females who are pregnant, nursing, or planning a pregnancy during the study.\n* Evidence of greater than mild eyelid deformity (e.g., ectropion, entropion, ptosis).\n* Use of concomitant topical ocular medications during the study duration.\n* Individuals using systemic steroids, immunosuppressive agents and\u002For anti-cholinergic (e.g. cold and allergy medications, tricyclic antidepressants) for treatment of autoimmune connective tissue disease may not be enrolled in the study if they have not been on a stable dosing regimen for a minimum of 30 days prior to the visit.\n* Individuals with uncontrolled diabetes or history or evidence of peripheral neuropathy.\n* Active intraocular inflammatory conditions such as iritis.\n* Individuals wearing rigid gas permeable or scleral contact lenses within the previous six months of enrollment. Subjects can have worn soft lenses, but not within one month prior to enrollment.\n* Individuals using punctual plugs inserted within 30 days of study start.",{"count":286,"type":21},30,[52],"The purpose of this research study is to evaluate the effects of trehalose, an ingredient found in commercially available artificial tears, on the corneal barrier function. The investigators will assess corneal dryness and measure the relative corneal epithelial \"barrier\" function (the degree to which the cornea can prevent penetration of sodium fluorescein dye into the eye) after using eye drops that contain 3% trehalose for one month.",[27],[291,292,293],"dry eye","trehalose","artificial tears","2026-04-30",{"date":137,"type":32},{"date":225,"type":32},{"date":298,"type":21},"2027-04",{"name":300,"class":120},"Southern California College of Optometry at Marshall B. Ketchum University",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":308,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":4},"100635611","blinking-exercise-study-100635611","NCT07554937","Blinking Exercise Study","Optimizing Blinking Exercises to Improve Dry Eye Disease in Patients With Glaucoma","Inclusion Criteria:\n\n* 18 years of age or older.\n* Those in the intervention group must have a confirmed diagnosis of glaucoma and be using at least one topical antiglaucoma medication.\n* Control participants must be glaucoma suspects who have not yet commenced topical therapy.\n\nExclusion Criteria:\n\n• Glaucoma patients who have had ocular surgery within the previous six months, contact lens wear, systemic inflammatory or autoimmune diseases affecting the ocular surface, or other ocular surface disorders such as severe blepharitis or keratoconjunctivitis sicca.",true,{"count":310,"type":21},45,[153],"The goal of this clinical trial is to evaluate whether a structured blinking exercise can improve symptoms and signs of dry eye disease (DED) in adults with glaucoma who are using topical intraocular pressure-lowering medications. The study will also assess the effects of the intervention on tear film stability, blink function, and participant adherence to the exercise.\n\nThe main questions this study aims to answer are:\n\nDoes a two-week structured blinking exercise reduce dry eye symptoms, as measured by the Ocular Surface Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE) questionnaires? Does the blinking exercise improve objective measures of ocular surface health, including non-invasive tear break-up time (NITBUT) and blink dynamics?\n\nResearchers will compare glaucoma patients receiving topical medications (intervention group) with glaucoma suspects not using topical therapy (control group) to evaluate the effectiveness of the blinking exercise on dry eye outcomes.\n\nParticipants in both groups will receive instruction on a standardized blinking exercise protocol consisting of repeated close-squeeze-open blinking cycles performed three times daily for two weeks. Participants will attend study visits at baseline, 2 weeks (post-intervention), and 4 weeks (follow-up). At each visit, participants will complete validated dry eye questionnaires and undergo non-invasive assessments of tear film stability, blink characteristics, and meibomian gland function. Adherence to the blinking exercise will be monitored using self-reported logs or reminders.",[27,314],"Glaucoma",[77,316,314,317,318,319],"Ocular Surface Disease","Blinking Exercise","Behavioral Intervention","Medication Adherence","2026-04-28",{"date":322,"type":32},"2026-05-04",{"date":324,"type":21},"2026-08",{"date":181,"type":21},{"name":327,"class":120},"St. Joseph's Healthcare Hamilton",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":40},"100585168","the-effect-of-01-topical-ciclosporin-a-for-12-weeks-on-the-eye-surface-immune-cells-in-dry-eyes-100585168","NCT06898853","The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes","The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Ocular Surface Innate and Adaptive Immune Response in Dry Eye Disease","Inclusion Criteria:\n\n1. 18 years of age and above\n2. Participants should meet any two of the following DED diagnostic criteria: i) ocular surface disease index score of ≥23 and ii) Oxford staining score of ≥1 iii) Tear meniscus height \\\u003C 0.2 mm.\n\nExclusion Criteria:\n\n1. Participants currently using or with previous use of steroids, ciclosporin, lifitegrast or any anti-inflammatory eye drops in the last 6 months.\n2. Participants with systemic CsA or tacrolimus\n3. Known hypersensitivity or contraindication to the study medication or any of its ingredients.\n4. Active intraocular inflammation.\n5. Contact lens wear or the use of contact lenses in the last 4 weeks.\n6. Active eye infections or history of critical illness.\n7. DED secondary to Steven-Johnson syndrome and cicatricial conjunctival disease.\n8. Participants with other ocular co-morbidities and medications for glaucoma.\n9. Participants with previous history of ocular surgery in the past 6 months.\n10. Any other active or inactive systemic condition, structural abnormality such as eyelid malposition's that in the judgment of the investigator could confound study assessments or limit compliance.\n11. Pregnant\u002Fbreastfeeding women",{"count":50,"type":21},[153],"Dry eye disease (DED) is a common, long-lasting condition that affects the surface of the eye. It happens when there's a problem with tear production or quality, which can lead to inflammation and discomfort. The immune system plays a big role in how DED develops and continues.\n\nResearchers have found that in people with DED, there are more immune cells and inflammatory substances in the tears and on the eye's surface. This includes various types of immune cells, like T cells and dendritic cells, which are part of the body's defense system.\n\nThe first treatment for DED is usually artificial tears, but because the condition is chronic and can flare up, clinicians often use anti-inflammatory treatments too. One such treatment is cyclosporine A (CsA), which comes as eye drops. CsA works by reducing inflammation and affects how immune cells behave.\n\nResearchers can study the immune cells on the eye's surface using a special microscopy technique called in vivo confocal microscopy (IVCM). A newer version of this method, called functional IVCM (Fun-IVCM), allows researchers to watch how these cells move and behave over time.\n\nIn the current study, researchers want to compare 0.1% CsA with a lubricating eye drop to see how they affect the immune cells on the eye's surface. The researchers will use Fun-IVCM to look at the number, shape, and movement of immune cells of the eye. The researchers will also collect samples from the eye's surface and tears to measure various markers of inflammation.\n\nThe goal is to better understand how CsA works in treating DED by directly observing its effects on the immune response in the eye, which is unexplored. This could help improve treatments for people suffering from this condition and expand the use of CsA in DED.",[27],{"date":137,"type":32},{"date":341,"type":32},"2025-06-01",{"date":343,"type":21},"2026-12-30",{"name":345,"class":120},"The University of New South Wales",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":363,"leadSponsor":364,"locationsCount":4},"100633685","phase-3-a-prospective-multicenter-randomized-controlled-trial-to-evaluate-the-efficacy-and-safety-of-amnion-membrane-disc-allograft-versus-standard-of-care-in-participants-with-moderate-to-severe-dry-eye-disease-100633685","NCT07529899","A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft Versus Standard of Care in Participants With Moderate to Severe Dry Eye Disease","BLINK","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Corneal Fluorescein Staining (CFS) Modified NEI grade \\> 15 in the study eye.\n3. Distance best corrected visual acuity better than 20\u002F60 Snellen equivalent in each eye\n4. Participant failed at least one conservative therapy (artificial tears or topical lubrication) in the previous six months.\n5. Participant must be able to follow study instructions, with the intention of completing all required visits\n6. Participant must agree to attend the study visits required by the protocol.\n7. Participant must be able and willing to complete follow-up.\n8. Participant must be willing and able to participate in the informed consent process.\n\nExclusion Criteria:\n\n1. Presence of persistent corneal epithelial defect or ulcer in either eye\n2. Presence of active ocular infection in either eye\n3. Presence of ocular inflammation that is not related to keratoconjunctivitis sicca, e.g., allergy, severe blepharitis\n4. Presence of other corneal disorder(s) that give rise to reduced corneal sensitivity, such as recurrent herpes keratitis\n5. Presence of corneal diseases other than dry eye that can disturb the pre-corneal tear film such as epithelial basement membrane dystrophy (EBMD)\n6. Contact lens wear\n7. History of recent ocular surgery\u002Ftrauma, which could affect corneal sensitivity, e.g., corneal transplantation, LASIK\n8. Presence of cicatricial ocular surface diseases\n9. History of procedures listed in 6.7.1 within the specified washout period\n\n   CONFIDENTIAL\n\n   Version No. 1 Version Date 06APR2026\n\n   Page PAGE 67 of NUMPAGES 67\n\n   VERSION 1.0 CELLUTION BIOLOGICS INC. 06 APRIL 2026\n10. History or use of any medications listed in 6.7.2 within the specified washout period\n11. Ophthalmic use of amniotic membrane in the past 90 days.\n12. Participants of childbearing potential who are pregnant, considering becoming pregnant within the next 6 months, and\u002For are unwilling to utilize an appropriate form of contraception.\n13. Medical or psychological condition that, in the opinion of the investigator, may interfere with study.\n14. Sensitivity to ofloxacin, vancomycin, or amphotericin antibiotics.\n15. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.",{"count":354,"type":21},40,[241],"To evaluate the efficacy of Lyophilized Human Amnion Membrane Disc in reducing corneal epithelial damage as measured by the Lexitas Modified National Eye Institute (NEI) Grading Scale for Corneal Fluorescein Staining.",[27],[270],"2026-04-08",{"date":361,"type":32},"2026-04-14",{"date":34,"type":21},{"date":61,"type":21},{"name":365,"class":39},"Cellution Biologics",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":17,"minAge":372,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":212,"phases":4,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100633334","effect-of-dry-eye-disease-on-accuracy-of-intraocular-lens-power-calculation-before-phacoemulsification-100633334","NCT07525336","Effect of Dry Eye Disease on Accuracy of Intraocular Lens Power Calculation Before Phacoemulsification","Inclusion Criteria:\n\n* Age equals to or above 40 years old\n* cataract patient\n* suitable for phacoemulsification\n* clear corneal media\n\nExclusion Criteria:\n\n* previous corneal surgery\n* advanced glaucoma\n* corneal pathology (keratoconus, scarring)\n* retinal disease affecting vision\n* irregular astigmatism\n* contact lens use within the last 2 weeks","40 Years",{"count":129,"type":21},"This study aims to determine the effect of dry eye disease on intraocular lens power calculation and the postoperative refractive outcome.",[27,376],"Cataract (Post-operative Cataract Surgery Follow-up)",[378,379,380,381],"dry eye disease","biometry","refractive surprise","phacoemulsification","2026-04-07",{"date":384,"type":32},"2026-04-13",{"date":294,"type":21},{"date":387,"type":21},"2029-04-30",{"name":389,"class":120},"Assiut University",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100633287","effect-of-behavioral-intervention-baduanjin-alone-or-laughter-exercise-plus-artificial-tears-versus-artificial-tear-on-dry-eye-disease-a-randomised-controlled-trial-100633287","NCT07524725","Effect of Behavioral Intervention (Baduanjin Alone or Laughter Exercise Plus Artificial Tears) Versus Artificial Tear on Dry Eye Disease: a Randomised Controlled Trial","Inclusion Criteria:\n\n* ≥18 TO ≤45 years of age, any sex.\n* Meet the dry eye diagnostic criteria of the DEWS international consensus, and show both of the following two conditions: OSDI score between 18 and 80; NIBUT (Non-invasive tear break-up time) \\\u003C 8 seconds\n* Best corrected visual acuity ≥ 0.5(10\u002F20) (in each eye).\n* Intraocular pressure between 5 and 21 mmHg (in each eye).\n* Women of childbearing potential must agree to use safe contraception during the study.\n* Willingness\u002Fability to return for all study visits and to follow instructions from the study investigator and their staff.\n* Voluntary participation and signing of the informed consent form approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* NEI corneal fluorescein staining score \\> 5 (in either eye).\n* Wore contact lenses within the past 14 days and cannot commit to not wearing them during the study period (3 months) (in either eye).\n* Received refractive surgery (LASIK, SMILE) or other ocular surgery, or had ocular trauma within the past 12 months (in either eye).\n* Had acute allergic conjunctivitis, infection, or ocular surface inflammation within the past 3 months (in either eye).\n* Eyelid abnormalities that affect eyelid function, such as nystagmus, blepharospasm, ectropion, entropion, or severe trichiasis (in either eye).\n* Previously diagnosed with glaucoma and received medical or surgical treatment (in either eye).\n* Currently receiving other ophthalmic or systemic treatments that may affect the tear film.\n* Allergy to fluorescein sodium.\n* Have a serious health condition that may limit their ability to participate.\n* Pregnant, breastfeeding, or planning to become pregnant.\n* Diagnosed with neurological or psychiatric disorders (e.g., severe anxiety, depression, or severe sleep disorder).\n* Have difficulty with physical movement.\n* Previous experience with traditional exercise such as Baduanjin.\n* Previous experience with laughter exercise.","65 Years",{"count":398,"type":21},540,[153],"The goal of this clinical trial is to compare the effect of behavioral intervention (Baduanjin alone or laughter exercise plus artificial tears) versus artificial tears in patients with dry eye disease.\n\nThe main questions it aims to answer are:\n\n* Does the Baduanjin improve the Ocular Surface Disease Index score of patients with dry eye disease?\n* Does the laughter exercise plus artificial tears improve the Ocular Surface Disease Index score of patients with dry eye disease?\n\nResearchers will compare behavioral intervention (Baduanjin alone or laughter exercise plus artificial tears) versus artificial tears to see if behavioral intervention works to treat dry eye disease.\n\nParticipants will：\n\n* Do the Baduanjin 5 times per week, or do laughter exercise plus artifical tears 4 times per day, or use artificial tears alone 4 times per day for 12 weeks\n* Visit the clinic once right before the intervention and the 4, 8, 12, 16, 24, 36, and 48 weeks after starting the intervention for checkups and tests\n* Use the app developed by our study to record the behavioral intervention and\u002For use of eye drops.",[27],"2026-04-05",{"date":384,"type":32},{"date":405,"type":21},"2027-01-01",{"date":407,"type":21},"2033-12-31",{"name":164,"class":120},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":142},"100611645","phase-4-systane-pro-vs-miebo-in-dry-eye-disease-100611645","NCT07243275","SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease","Comparing the Efficacy of SYSTANE® PRO to MIEBO™ for the Treatment of Dry Eye Disease","Inclusion Criteria:\n\n* Adults\\>=18 years of age\n* Corrected visual acuity of 20\u002F100 or better in both eyes\n* Ocular Surface Disease Index \\[OSDI\\] scores between 23 and 50 units \\[inclusive\\]\n* Tear break up time score of \\\u003C=5 seconds in both eyes\n* Schirmer I test (without anesthesia) \\>=5 mm in both eyes\n\nExclusion Criteria:\n\n* Discontinue contact lens wear starting 7 days prior and throughout the study\n* Artificial tears and warm compresses should not be used for at least one week prior to enrollment and throughout the study\n* Systemic health conditions that are known to alter tear film physiology(e.g., primary and secondary Sjogren's syndrome)\n* History of ocular surgery within the past 12 months\n* History of severe ocular trauma, active ocular infection or inflammation, have ever used Accutane or are currently using ocular medications.\n* Women who are pregnant or breast feeding(self report)\n* Subjects with a condition or in a situation, which in the investigator's opinion, may put the subject at significant rist, may confound the study results, or may significantly interfere with their participation in the study\n* Subjects will not be allowed to use any other topical eye drops or other dry eye treatments beyond their assignment during the study\n* Participants in clinical trial or study using a device, topical, or oral therapeutic in the past 3 months of enrollment",{"count":417,"type":21},260,[52],"This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.",[27],"2026-03-26",{"date":423,"type":32},"2026-03-27",{"date":425,"type":32},"2026-02-18",{"date":427,"type":21},"2026-09-30",{"name":429,"class":120},"Indiana University",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":443,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":4},"100585705","phase-2-evaluation-of-allogenic-mesenchymal-stem-cell-msc-injection-therapy-for-refractory-graft-versus-host-disease-gvhd-unresponsive-to-conventional-treatments-100585705","NCT06905834","Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments","A Phase IIB Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments","TER-EYE","Inclusion Criteria:\n\n* Patients over 18 years of age who understand and sign the informed consent form.\n* Diagnosis of severe GVHD (graft versus host disease) according to NIH criteria (revised by Lee SJ in 2017) with ocular involvement in the form of severe SOD (severe ocular disease) in both eyes for more than 3 months, objectively defined as superficial punctate keratitis \\>2 on the Oxford scale (range 0-5) and\u002For the presence of epithelial defect, and subjectively as severe symptoms, \\>33 points on the OSDI questionnaire (0-100).\n* Patients must have previously been treated for at least three months with blood derivatives and\u002For insulin eye drops and topical cyclosporine or tacrolimus (unless any of these treatments were not tolerated and had to be discontinued).\n* Patients must be using ocular lubricants at least 4 times a day and, despite this, still meet the criteria for severe SOD as outlined in point 2.\n* Patients on low doses of topical corticosteroids for maintenance should have a stable dose for at least one month prior to inclusion.\n* The dose and frequency of all topical medications the patient begins the trial with must remain unchanged throughout the duration of the trial, unless otherwise judged by the investigator.\n* The chronic GVHD systemic treatment should be stable regarding the use of systemic immunosuppressors for at least one month prior to patient inclusion or before starting treatment.\n* Negative result in the urine pregnancy test at the baseline visit for women of childbearing age. Subjects must be advised to use contraceptive methods during their participation in the clinical trial and undergo a new pregnancy test at the treatment visit if more than 28 days have passed since the baseline visit.\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease or any condition that, in the medical judgment, could put the patient at risk or affect the interpretation of the results.\n* Uncontrolled systemic GVHD.\n* Active ocular infection.\n* Ocular surgery within the last 3 months.\n* Initiation of topical therapies for SOD indicated in the inclusion criteria less than 3 months prior to inclusion.\n* Start of topical corticosteroid use within 4 weeks prior to inclusion.\n* Cognitive impairments that could interfere with study compliance.\n* Pregnant women or women during the lactation period.",{"count":286,"type":21},[24],"This Phase IIB, multicenter, double-blind, randomized, and uncontrolled clinical trial aims to assess the efficacy and safety of subconjunctival injection of Mesenchymal Stem Cells (MSCs) in patients with Graft-versus-Host Disease (GVHD) and severe ocular involvement (DYD-dry eye disease). The primary objective is to evaluate the clinically and statistically significant improvement in the signs and symptoms associated with the disease.\n\nSecondary objectives include:\n\n* Analyzing adverse events related to the subconjunctival injection of MSCs to confirm the safety of this treatment in patients with GVHD ocular involvement.\n* Identifying new biomarkers that can be used to objectively assess the progression of patients with GVHD and severe ocular involvement.\n* Studying the relationship between the expression of ocular surface-specific markers by MSCs and their clinical efficacy, as well as the variation in the expression of these markers in relation to cell preservation methods.\n\nAssessing the quality of life of patients treated with two doses of MSCs using the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire).\n\n\\- Evaluating whether the cell dose impacts clinical improvement.\n\nThe trial includes 30 patients, divided into two groups of 15, and focuses on the assessment of dry eye disease, with the treatment based on MSC administration to improve clinical outcomes and quality of life for the patients.",[27,442],"Graft-Versus-Host Disease(GVHD)",[378,444,445],"Graft-versus-Host Disease","mesenchymal stem cells","2026-03-24",{"date":423,"type":32},{"date":449,"type":21},"2026-05",{"date":451,"type":21},"2028-06",{"name":453,"class":120},"Instituto de Investigación Biomédica de Salamanca",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":478},"100624686","clinical-investigation-between-the-topical-administration-of-a-tear-substitute-with-ancillary-medicinal-substance-and-hyaluronic-acid-03-fbv01-vs-hyaluronic-acid-03-in-subjects-in-the-treatment-from-moderate-to-severe-ded-100624686","NCT07412860","Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED","Interventional, Multi-center, Randomized, Controlled, Open Label Clinical Investigation Between the Topical Administration of a Tear Substitute Containing Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) Versus Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe Dry Eye Syndrome","Inclusion Criteria:\n\n* Patients able to provide written Informed Consent, in accordance with good clinical practice and current legislation;\n* Patients (male and female) 18 years of age or older with moderate to severe dry eye syndrome or with dry eye syndrome, even after eye surgery (e.g. refractive surgery or cataract);\n* Moderate to severe dry eye syndrome in one or both eyes in the presence of:\n\n  1. Dry Eye Symptom Assessment Questionnaire (SANDE) \\> 60;\n  2. Tear Film Break-Up Time (TFBUT) \\\u003C 7 seconds. TFBUT value will be recorded as an average of 3 measurements;\n  3. Test di Schirmer \\\u003C 10 mm;\n* Diagnosis of dry eye syndrome for at least 6 months (use or recommendation of use of artificial tears\u002Flubricants for the treatment of dry eye);\n* Patients able to understand the nature and purpose of the study, including possible risks;\n* Patient able to cooperate with the Investigator and meet the requirements of the clinical investigation plan;\n* Patient who, in the opinion of the Investigator, will benefit from this treatment;\n* Patient available for the entire study period.\n\nExclusion Criteria:\n\n* Eye infection or clinically significant inflammation in both eyes (for example: Herpes simplex infections, corneal virus infections, bacterial, viral or fungal conjunctivitis, tuberculosis and mycosis of the eye, purulent and herpetic blepharitis, stye);\n* History or evidence of eyelid abnormalities in either eye;\n* Use of topical cyclosporine, topical corticosteroids, or any other topical medication for the treatment of ocular pathologies in either eye within 7 days of study enrollment;\n* Patients being treated with chronic systemic therapies with analgesic, anti-inflammatory, corticosteroids, or opioids;\n* History of ocular surgery (including laser procedures or refractive surgery) in either eye 7 days prior to enrollment;\n* History or evidence of severe or uncontrolled systemic or autoimmune disease does not allow participation in the study or could impair the results;\n* Patients being treated with drugs and\u002For medical devices and\u002For supplements for neuropathic pain (e.g., SNRIs (duloxetine, venlafaxine), pregabalin, gabapentin, TCAs (nortriptyline, amitriptyline));\n* Patient with known or potential allergy or hypersensitivity and\u002For history of allergic reactions to one of the components of the medical device;\n* Participation in another clinical trial within 30 days prior to the screening visit;\n* History of administration or abuse of drugs, medications, or alcohol;\n* Women of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) will be excluded from participation in the study if they meet any of the following conditions:\n\n  1. are currently pregnant or,\n  2. have a positive urine pregnancy test result at visit 1,\n  3. intend to become pregnant during the study treatment period or,\n  4. are breastfeeding or, unwilling to resort to highly effective birth control measures, such as: hormonal contraceptives oral, implanted, transdermal or injected and\u002For mechanical barrier methods spermicidal concurrently with a barrier such as a condom or diaphragm or IUD during the entire course of the study and 30 days after the end of the treatment period;\n* Subject unable to follow clinical investigation procedures and follow-up visits;\n* Any other medical condition which, in the opinion of the Investigator, could influence participation in the clinical investigation or compromise its results.",{"count":462,"type":21},74,[153],"The goal of this clinical investigation plan is to evaluate the performance, tolerability, safety, and compliance of an ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV\\_01) compared with hyaluronic acid 0.3% alone in adult men and women (≥18 years) with moderate-to-severe dry eye syndrome.\n\nThe main questions it aims to answer are:\n\n* Is the ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid non-inferior in improving the clinical performance outcomes of dry eye compared with hyaluronic acid alone?\n* Is the investigational device safe and well tolerated, with acceptable partecipant compliance over the treatment period?\n\nResearchers will compare the medical device containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV\\_01) to hyaluronic acid 0.3% alone to see if the combination provides at least equivalent clinical benefit without increased safety issues.\n\nParticipants will be randomly assigned (1:1) to one of two treatment groups in a multicenter, prospective, randomized, open-label, controlled study. Participants will instill 1 drop in both eyes 4 times daily (every 4 ± 1 hours) for 30 ± 4 days and attend study visits for assessments of dry eye signs and symptoms, safety, tolerability, and treatment compliance. The study plans to enroll 74 partecipants, with an enrollment period of about 11 months and a total study duration of approximately 12 months (from first partecipant first visit to last partecipant last visit).",[466,27],"Dry Eye Syndromes",[468,378],"moderate to severe dry eye syndrome","2026-02-09",{"date":471,"type":32},"2026-02-17",{"date":473,"type":32},"2025-03-26",{"date":475,"type":21},"2026-03-31",{"name":477,"class":39},"FB Vision S.p.A",2,{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":17,"minAge":487,"maxAge":372,"enrollmentInfo":488,"targetDuration":4,"studyType":22,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":501,"locationsCount":142},"100623423","phase-4-supplementary-kelulut-honey-therapy-in-juvenile-open-angle-glaucoma-effects-on-il-6-rnfl-and-dry-eye-100623423","NCT07396441","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye","Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye.","HONEY-JOAG","Inclusion Criteria:\n\nJOAG patients age 15 years old and above until 40 years old at the time of diagnosis Compliant to conventional treatment achieved target intraocular pressure\n\nExclusion Criteria:\n\nPatients with allergy to honey or honey-based products OCT signal less than 6\u002F10 Concurrent retinal diseases and other optic neuropathies Systemic neurodegenerative disease Systemic comorbidities such as diabetes mellitus and autoimmune diseases Patients on other honey-based products for the last 3 months Patient who consumes honey-based products during the study duration of 3 months (monitoring via honey-diary, return of the used sachet during the follow up visits) Patients on anti-oxidants, traditional medications or herbal products for the last 3 months Topical usage of steroids, systemic steroids and non-steroidal anti-inflammatory drugs.\n\nSepsis Compliance less than 75%.","15 Years",{"count":50,"type":21},[52],"The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.",[492,27,493,494,495],"Juvenile Open Angle Glaucoma","Interleukin 6","Retinal Nerve Fiber Layer Thickness","HbA1c Level","2026-02-03",{"date":469,"type":32},{"date":499,"type":32},"2026-01-15",{"date":57,"type":21},{"name":502,"class":120},"Universiti Sains Malaysia",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":372,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":520,"locationsCount":40},"100623539","phase-4-rebamipide-versus-diquafosol-for-perioperative-dry-eye-in-cataract-surgery-100623539","NCT07397949","Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery","A Randomized Noninferiority Trial Comparing Rebamipide and Diquafosol for Perioperative Dry Eye Management in Cataract Surgery","Inclusion Criteria:\n\n* Adults aged 40 years or older scheduled for unilateral cataract surgery\n* Presence of dry eye disease, defined by an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:\n\n  * Tear film breakup time (TBUT) ≤7 seconds\n  * Oxford corneal staining grade ≥1\n  * Schirmer's test value ≤10 mm\u002F5 minutes\n* Ability and willingness to comply with the study protocol and follow-up schedule\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Active ocular infection or inflammation, including infectious keratitis\n* History of ocular surgery other than cataract surgery in the study eye\n* Use of topical medications that may affect the ocular surface (e.g., intraocular pressure-lowering eye drops)\n* Any ocular or systemic condition judged by the investigator to interfere with study participation or outcome assessment",{"count":50,"type":21},[52],"This clinical trial is designed to compare two commonly used eye drop treatments for dry eye disease in patients undergoing cataract surgery.\n\nDry eye disease is common in people who need cataract surgery and may worsen before or after surgery, causing eye discomfort, blurred vision, and unstable vision. Proper management of dry eye before and after surgery may help improve eye comfort and the accuracy of vision outcomes.\n\nIn this study, patients with mild to moderate dry eye disease who are scheduled for cataract surgery will be randomly assigned to receive one of two treatments:\n\nRebamipide eye drops, or\n\nDiquafosol eye drops\n\nParticipants will begin using the assigned eye drops one month before cataract surgery and continue treatment for three months after surgery. The eye drops will be used only in the eye undergoing surgery.\n\nResearchers will examine whether one treatment is as effective as the other in improving tear film stability and reducing dry eye symptoms around the time of cataract surgery. Eye examinations and questionnaires will be performed before surgery, on the day of surgery, and during follow-up visits after surgery.\n\nThe information gained from this study may help doctors choose the most appropriate treatment for managing dry eye disease in patients undergoing cataract surgery.",[27,514],"Cataract","2026-02-02",{"date":469,"type":32},{"date":518,"type":21},"2026-03",{"date":181,"type":21},{"name":521,"class":120},"Samsung Medical Center",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":539,"leadSponsor":541,"locationsCount":4},"100621342","efficacy-and-safety-of-vmx-eye-drops-for-dry-eye-disease-100621342","NCT07369375","Efficacy and Safety of VMX Eye Drops for Dry Eye Disease","Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VMX Eye Drops for the Treatment of Dry Eye Disease (DED)","Inclusion Criteria:\n\n* Patients with an age of ≥ 18 and ≤ 80 years\n* Patients with a diagnosis of Dry Eye (mild\u002Fmoderate) with at least one of the following:\n\n  * Tear Osmolarity \\>308 mOsm\u002FL\n  * TBUT \\\u003C 10 seconds\n  * Schirmer I test ≥ 5 mm and ≤ 14 mm at 5 minutes\n* Patients not treated with artificial tears for at least 7 days\n* Patients not treated with artificial tears for at least 7 days\n\nExclusion Criteria:\n\n* Use of systemic medications which may affect a dry eye condition within 1 month prior to study enrolment (e.g. low-dose aspirin, antihistamines, decongestants, antipsychotics, parkinsonism medications, anticholinergics, oral isotretinoin, and oral diazepam)\n* Patients with a score of ≤ 4 mm at 5 minutes on the Schirmer I test\n* Patients that suffer of ocular allergy pathology (seasonal and chronic)\n* Ongoing ocular or systemic infectious conditions\n* Use of topical ocular therapies that cannot be suspended for the entire duration of the study\n* Use of topical antibiotics and or corticosteroids within 15 days prior to study enrolment\n* Use of systemic antibiotics and or corticosteroids within 1 month prior to study enrolment\n* Any intraocular surgery in the past 12 months or require any intraocular surgery during the study\n* Acute and Chronic Conjunctival Disease\n* Eyelid surgery within the 6 months prior to study enrolment\n* Presence of congenitally absent lacrimal or Meibomian glands or have any obstructive disease of the lacrimal glands\n* History of ocular herpetic keratitis or active blepharitis in the 4 weeks prior to study enrolment\n* History of autoimmune diseases\n* Inflammations or abnormalities in the eyelid, in accordance with PI's clinical judgment\n* History of corneal diseases, as keratoconus\n* History of corneal transplant in one or both eyes\n* Keratinization of the eyelid margin\n* History of Sjögren's syndrome\n* History of corneal trauma in the last 4 weeks prior to study enrolment\n* Patients who are unwilling to discontinue all artificial tears and use only the study product ad indicated for the duration of the study\n* Inability to self-administer study medications\n* Women of childbearing potential who are pregnant, breast feeding, plan to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study.\n* Any hypersensitivity to the use of the study product formulations or an allergy to any ingredients contained within product formulation\n* Participation in other clinical studies involving drugs or devices within 30 days prior to study enrolment.\n* Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial\n* Patients unable or unwilling to comply with appointments or all protocol requirements","80 Years",{"count":531,"type":21},76,[153],"This multicenter, randomized, double-blind study evaluates the safety and effectiveness of VMX eye drops in patients with dry eye disease. It aims to improve tear film stability, reduce dry eye symptoms, and enhance patients' quality of life compared to standard treatment.",[27],"2026-01-27",{"date":537,"type":32},"2026-01-29",{"date":515,"type":21},{"date":540,"type":21},"2026-06",{"name":542,"class":39},"VISUfarma SpA",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":22,"phases":553,"briefSummary":554,"conditions":555,"keywords":556,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":40},"100563383","impact-of-tixel-treatment-on-symptoms-and-signs-in-patients-with-dry-eye-disease-100563383","NCT06615453","Impact of Tixel Treatment on Symptoms and Signs in Patients With Dry Eye Disease","A Prospective Study Assessing the Impact of Tixel Treatment of Peri Orbital Wrinkles on Symptoms and Signs in Patients With Dry Eye Disease","TIXEL-DED","Inclusion Criteria:\n\n1. Mild to Moderate Periorbital wrinkles\n2. OSDI score of at least 23\n3. Noninvasive Tear film break up time (NIBUT) ≤ 10 seconds\n4. No other eye or skin or immune problems\n5. Willing and able to provide written informed consent.\n6. Willing to participate in all study activities and instructions.\n\nExclusion Criteria:\n\n1. Pregnancy and\u002For breastfeeding\n2. Lesions in the periorbital area\n3. Acute severe blepharitis\n4. Acute conjunctivitis\n5. Use of eye drops within 2 hours before examination\n6. Other concomitant anterior eye disease\n7. Has undergone outdoors\u002Fsunbed tanning during the last 4 weeks\n8. Is unwilling to follow the Tixel aftercare instructions after each of the three Tixel treatments.\n9. Active Herpes Simplex or tendency for Herpes Simplex in the periorbital area (meaning the subject has had the condition previously).\n10. Current skin cancer, malignant sites and\u002For advanced premalignant lesions or moles in the treatment area.\n11. An impaired immune system condition or use of immunosuppressive medication.\n12. Collagen disorders, keloid formation and\u002For abnormal wound healing.\n13. Previous invasive\u002Fablative procedures in the areas to be treated within 3 months prior to initial treatment or plans for such treatment during the course of the Tixel2 device treatment, or before complete healing of such treatments has occurred.\n14. Any patient who takes or has taken any medications (including via topical application), herbal treatment (oral or topic), food supplements or vitamins, which may cause fragile skin or impaired skin healing during the last 3 months.\n15. Any patient who has used oral Isotretinoin (Accutane® or Roaccutan®) within 3 months prior to treatment or less.\n16. Any patient who has a history of bleeding coagulopathies or use of anticoagulants.\n17. Any patient who has tattoos or permanent makeup in the treated area.\n18. Any patient who has burned skin, blistered skin, irritated skin, or sensitive skin in any of the areas to be treated.\n19. Any patient who underwent thread lifting of the area to be treated in the last 3 months.",{"count":552,"type":21},36,[153],"This study will examine how a standard Tixel treatment versus a sham treatment for eye wrinkles affects the symptoms and signs of Dry Eye Disease.",[27],[557],"Dry eye disese, Tixel treatment","2026-01-23",{"date":560,"type":32},"2026-01-26",{"date":562,"type":32},"2024-09-17",{"date":564,"type":21},"2026-07-31",{"name":566,"class":120},"Aston University",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":308,"sex":17,"minAge":573,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":576,"briefSummary":577,"conditions":578,"keywords":579,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":4},"100619215","telemedicine-for-evaluating-dry-eye-disease-ded-using-a-mobile-phone-attached-portable-automatic-ocular-surface-imaging-device-paosid-a-patient-operated-diagnostic-and-continuous-ocular-surface-monitoring-cosm-system-100619215","NCT07341724","Telemedicine for Evaluating Dry Eye Disease (DED) Using a Mobile Phone-Attached Portable Automatic Ocular Surface Imaging Device (PAOSID): A Patient-Operated Diagnostic and Continuous Ocular Surface Monitoring (COSM) System","Inclusion Criteria:\n\n1. Participants diagnosed as DED by experienced ophthalmologists, based on the TFOS DEWS II (The Tear Film and Ocular Surface Society Dry Eye Workshop II) guidelines,(19) as well as healthy individuals with no ocular conditions who voluntarily agreed to participate in the study;\n2. Participants, or their companions or caregivers, who are willing and able to use the study smartphone to capture relevant eye images and videos;\n3. Aged 21 years or older;\n4. Provide informed consent.\n\nExclusion Criteria:\n\n1. Participants with ocular surface disorders other than DED that may affect the appearance of the ocular surface (e.g., pterygium, keratitis, corneal scarring) or with any organic pathologies impacting vision (e.g., cataracts, glaucoma, retinal diseases).\n2. Patients currently wearing scleral lenses or bandage contact lenses.\n3. Significant changes in the ocular images since diagnosis due to factors such as postdiagnostic treatment;\n4. Unable to cooperate with the PAOSID, such as due to a serious mental illness or brain damage causing loss of limb control;\n5. Eyes with previous or active corneal diseases such as infectious keratitis, corneal opacity or dystrophy;\n6. Eyes with active inflammation or infection.","21 Years",{"count":575,"type":21},50,[153],"Dry eye disease (DED) is a common eye condition that is becoming more widespread. Detecting it early, keeping track of its progression, and following up regularly can help protect vision and prevent serious complications. However, due to a shortage of ophthalmologists, limited access to eye care services, and disparities in care quality, many patients receive infrequent or insufficient clinical consultations.\n\nTo address these needs, a portable automatic ocular surface imaging device (PAOSID) that attaches to a mobile phone has been developed. This device uses three types of light including white, infrared, and cobalt blue light to capture clear images and videos of the eye's surface.\n\nIt also has a smart system that automatically takes high-quality images, allowing patients to use it at home independently. This device may help detect early signs of DED and monitor eye health more easily.",[270,27],[580,581],"PAOSID","Dr EYE","2026-01-06",{"date":584,"type":32},"2026-01-14",{"date":586,"type":21},"2026-01-09",{"date":588,"type":21},"2026-12-31",{"name":590,"class":184},"Singapore National Eye Centre"]